6 Search Results


Search Again

James Dai , PhD

Email: jdai@fredhutch.org

Phone: (206) 667-6364

James Dai’s Lab works in statistical genetics and genomics, design and analysis of randomized clinical trials, statistical methods for high-dimensional feature selection and prediction, gene-treatment interaction, mediation and instrumental variables regression. Methodologically, his lab is also interested in cancer genomics topics, for example integrative genomic analyses and intra-tumor heterogeneity. The overarching scientific interest is to discover and validate and genomic markers that drive cancer etiology, predict cancer prognosis and treatment efficacy.

View Bio

Jeff Delrow , PhD

Email: jdelrow@fredhutch.org

Phone: (206) 667-2763

Dr. Delrow is the director of the bioinformatics resource at Fred Hutch. His primary role is to support researchers who need assistance with the analysis of genomics and proteomics data.

View Bio

Heather Gustafson , PhD

Email: heather.gustafson@seattlechildrens.org

Phone: (206) 884-7339

Dr. Gustafson's career has focused on harnessing existing and developing novel technology platforms that alter macrophage function through environmental manipulation. Her current research, involves engineering several macrophage phenotype targeting methods in order to understand these interactions. Her lab does this through the development of technology platforms that target specific macrophage phenotypes and alter macrophage phenotypes for therapeutic and diagnostic applications. Through the development and use of these technologies they can develop and understanding of how environmental cues impact macrophage function, how macrophage function drives disease progression and how to harness that information to engineer novel technologies to treat disease.

View Bio

Amy Paguirigan , PhD

Email: apaguiri@fredhutch.org

Phone: (206) 667-4352

The focus of my research has been the integration of emerging technologies to address clinically relevant questions in cancer biology. My focus is on the interface between clinical molecular biology, bioinformatics and biotechnology, in aiming to bridge the gaps to bring novel approaches in both the biotechnological and informatics realms to clinical molecular biology to study the role of clonal diversity in cancer therapy.

View Bio

Scott Tykodi , MD, PhD

Email: stykodi@fredhutch.org

Phone: (206) 606-7763

Dr. Tykodi treats patients with kidney cancer and melanoma. He is particularly interested in the application of immune therapies to the treatment of cancer. His research focus is in the clinical application and translational study of natural or induced T-cell immunity targeting renal cell carcinoma and other cancers.

View Bio

Takuma Uo , Ph.D.

Email: tuo@uw.edu

Phone: 206-897-5463

Age is the most common risk factor for prostate cancer, with the rapid rise in its incidence after age 50. As a member of the prostate cancer research group in Division of Gerontology and Geriatric Medicine, Dr. Uo is focused on understanding molecular logics behind adaptive resistance of prostate cancer cells to the most forefront androgen-targeted therapies. Specifically, his research program examines the cell autonomous and nonautonomous mechanisms that enable prostate cancer progression, including the constitutively-active isoforms of androgen receptor, the metabolic rewiring, and the extracellular fuel supply from tumor microenvironment and adipose tissues. He harnesses in-depth knowledge and advanced technologies of molecular, cellular, chemical, synthetic, and computational biology to help develop next-generation of therapeutics to improve patient survival.

View Bio